stoxline Quote Chart Rank Option Currency Glossary
  
MediWound Ltd. (MDWD)
16.08  -0.28 (-1.71%)    06-12 16:00
Open: 16.64
High: 16.64
Volume: 36,085
  
Pre. Close: 16.36
Low: 15.9
Market Cap: 149(M)
Technical analysis
2024-06-12 4:23:35 PM
Short term     
Mid term     
Targets 6-month :  20.65 1-year :  22.32
Resists First :  17.68 Second :  19.11
Pivot price 16.69
Supports First :  15.38 Second :  12.79
MAs MA(5) :  16.57 MA(20) :  16.85
MA(100) :  15.54 MA(250) :  11.88
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  34.5 D(3) :  44.7
RSI RSI(14): 42.3
52-week High :  19.86 Low :  7.09
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MDWD ] has closed above bottom band by 20.7%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.66 - 16.79 16.79 - 16.89
Low: 15.62 - 15.77 15.77 - 15.87
Close: 15.89 - 16.12 16.12 - 16.27
Company Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Headline News

Tue, 11 Jun 2024
MediWound (NASDAQ:MDWD) Stock Price Crosses Above Fifty Day Moving Average of $16.98 - Defense World

Mon, 03 Jun 2024
HC Wainwright Research Analysts Raise Earnings Estimates for MediWound Ltd. (NASDAQ:MDWD) - Defense World

Sat, 01 Jun 2024
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report - Simply Wall St

Sat, 01 Jun 2024
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported Its First-Quarter Results And Analysts Are ... - Yahoo Finance

Wed, 29 May 2024
MediWound: Q1 Earnings Snapshot - The Washington Post - The Washington Post

Wed, 29 May 2024
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 6 (M)
Held by Insiders 26.2 (%)
Held by Institutions 31.1 (%)
Shares Short 233 (K)
Shares Short P.Month 172 (K)
Stock Financials
EPS -1.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.5
Profit Margin -64.3 %
Operating Margin -75.3 %
Return on Assets (ttm) -14.2 %
Return on Equity (ttm) -45.2 %
Qtrly Rev. Growth 30.7 %
Gross Profit (p.s.) 0
Sales Per Share 2.13
EBITDA (p.s.) -1.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -11.83
PEG Ratio -0.1
Price to Book value 6.4
Price to Sales 7.51
Price to Cash Flow -9.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android